Literature DB >> 9609558

The impact of fetal compromise on outcome at the border of viability.

D G Batton1, D B DeWitte, R Espinosa, T L Swails.   

Abstract

OBJECTIVE: Our goal was to evaluate the impact of fetal compromise on the outcome of borderline viable babies. STUDY
DESIGN: All 142 babies born in our hospital from 1990 to 1995 with a gestational age of 23 to 25 weeks were included. Fetal compromise was considered present if one of the following was documented: a major anomaly, congenital sepsis, chronic intrauterine infection, intrauterine drug exposure, congenital anemia, severe growth restriction, fetal acidosis, or cardiorespiratory and neurologic depression in the delivery room.
RESULTS: The 43 babies who had at least one cause of fetal compromise had a lower birth weight (p < 0.001), but there were no other differences in demographics or complications of prematurity. The survival rate was significantly better for babies free of fetal compromise (75% vs 33%, p < 0.001), particularly for babies born at 23 weeks of gestation (75% vs 6%, p < 0.001). For surviving babies free of fetal compromise, the outcome at 23 weeks was comparable to that at 24 to 25 weeks for major causes of long-term neurologic morbidity.
CONCLUSIONS: Like advancing gestational age and increasing birth weight, the absence of fetal compromise has a major beneficial impact on the outcome of borderline viable babies that might be important when decisions are made about the appropriate level of support.

Entities:  

Mesh:

Year:  1998        PMID: 9609558     DOI: 10.1016/s0002-9378(98)70522-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  STRIDER: Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction--a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis.

Authors:  Wessel Ganzevoort; Zarko Alfirevic; Peter von Dadelszen; Louise Kenny; Aris Papageorghiou; Aleid van Wassenaer-Leemhuis; Christian Gluud; Ben Willem Mol; Philip N Baker
Journal:  Syst Rev       Date:  2014-03-11

2.  STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials.

Authors:  A Pels; L C Kenny; Z Alfirevic; P N Baker; Peter von Dadelszen; C Gluud; C T Kariya; B W Mol; A T Papageorghiou; A G van Wassenaer-Leemhuis; W Ganzevoort; K M Groom
Journal:  BMC Pregnancy Childbirth       Date:  2017-12-28       Impact factor: 3.007

3.  Prospective study of early and late outcomes of extremely low birthweight in Central Saudi Arabia.

Authors:  Mostafa A Abolfotouh; Saif Al Saif; Waleed A Altwaijri; Mohammed A Al Rowaily
Journal:  BMC Pediatr       Date:  2018-08-22       Impact factor: 2.125

4.  Increasing illness severity in very low birth weight infants over a 9-year period.

Authors:  David A Paul; Kathleen H Leef; Robert G Locke; Louis Bartoshesky; Judy Walrath; John L Stefano
Journal:  BMC Pediatr       Date:  2006-02-06       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.